Exploring How CQAs Affect the Function and Potency of AAV Gene Therapy Drug Products
Time: 1:30 pm
day: Conference Day Two
Details:
- Delving into the intricacies of specific CQAs relevant to AAV gene therapy products
- Exploring case studies demonstrating the correlation between CQAs and therapeutic outcomes
- Assessing how specific CQAs, such as viral titer, capsid integrity, and transgene expression, directly influence the functional and potency aspects of AAV gene therapy
